<DOC>
	<DOCNO>NCT02908074</DOCNO>
	<brief_summary>This 6 month , active treatment , extension study , open subject complete full 24 week Study MBGS205 ( A Phase IIb multicentre , double-blind , dose-ranging , randomised , placebo-controlled study evaluate safety efficacy BGS649 male obese subject hypogonadotropic hypogonadism [ HH ] ) .The main purpose Study MBGS206 evaluate bone mineral density long term safety efficacy parameter subject 12 month exposure BGS649 .</brief_summary>
	<brief_title>A 6 Month Safety Extension Study MBGS205 Evaluating Long Term Effects BGS649 Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<criteria>Participating Study MBGS205 completion 24 week treatment period without meet discontinuation criterion Study MBGS205 In opinion investigator compliant requirement Study MBGS205 protocol . Meeting discontinuation criterion initial Study MBGS205</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypogonadotropic</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone</keyword>
</DOC>